Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease.

Position Overview Nurix Therapeutics is seeking a Vice President, Medical Affairs, Hematology-Oncology to build, expand, and lead a best-in-class Medical Affairs organization supporting the company’s transition from a clinical-stage biotechnology company toward commercialization as its hematology-oncology portfolio advances into late-stage clinical development. This executive will provide strategic and operational leadership across the full Medical Affairs function, including medical strategy, ﬁeld medical, scientiﬁc communications, evidence generation, thought leader engagement, medical information, and launch readiness. The role will play a central role in shaping the scientiﬁc and medical strategy for Nurix’s targeted protein degradation portfolio and helping deﬁne the company’s external scientiﬁc leadership in hematologic malignancies.

The role will be a key cross-functional partner to Clinical Development, Commercial, Market Access, Regulatory, Legal, and Compliance as Nurix plans and executes future commercialization activities. This leader will contribute broadly to portfolio strategy, lifecycle planning, and enterprise-level decision making as a member of the senior leadership team.

Responsibilities

Lead and scale the Medical Affairs function to support the progression of Nurix’s hematology-oncology programs into late-stage clinical development and future commercial readiness. Own the overall Medical Affairs strategy for the hematology-oncology portfolio, ensuring alignment with development plans, portfolio priorities, and corporate objectives. Lead development of the scientiﬁc platform and differentiated medical narrative for Nurix hematology-oncology programs within rapidly evolving treatment landscapes.

Partner closely with Clinical Development to shape late-stage medical strategy, including data generation priorities, scientiﬁc narrative, external engagement plans, and lifecycle opportunities. Develop and execute integrated medical plans across ﬁeld medical, scientiﬁc communications, publications, medical education, medical information, insight gathering, and evidence generation. Expand and lead a high-performing MSL organization focused on credible scientiﬁc exchange, compliant insight capture, and strong engagement with key external experts, investigators, and treatment centers.

Lead external engagement in hematologic malignancies, including advisory boards, investigator relationships, disease-area thought leader engagement, and interactions with cooperative groups and broader scientiﬁc communities. Serve as a senior medical representative of the company with external experts, investigators, and scientiﬁc leaders, helping establish Nurix as a credible scientiﬁc leader in hematologic malignancies and targeted protein degradation. Direct publication and scientiﬁc communication strategy for key clinical data, congress presentations, medical content, symposia, and educational initiatives.

Lead integrated evidence generation strategies spanning registrational support, post-marketing evidence development, real-world evidence, health economics and outcomes research, treatment sequencing, and product differentiation opportunities.

Vice President, Medical Affairs – Hematology-Oncology